Breast Cancer Clinical Trials in Oklahoma City, Oklahoma
10 recruitingOklahoma City, Oklahoma
Showing 1–10 of 10 trials
Recruiting
Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
Breast CancerDepression
NRG Oncology402 enrolled277 locationsNCT06748222
Recruiting
Not Applicable
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast CancerCognitive Impairments
NRG Oncology386 enrolled680 locationsNCT05896189
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Early Phase 1
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
Breast CancerLymphoma
University of Oklahoma104 enrolled2 locationsNCT05921253
Recruiting
Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Breast Cancer
Canadian Cancer Trials Group2,140 enrolled475 locationsNCT03488693
Recruiting
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Breast CancerProstate Cancer
University of Oklahoma420 enrolled1 locationNCT07014618
Recruiting
Phase 2
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Breast Cancer
Criterium, Inc.70 enrolled19 locationsNCT04567420
Recruiting
Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Breast CancerBreast NeoplasmCancer of the Breast+1 more
Proton Collaborative Group132 enrolled9 locationsNCT01766297
Recruiting
Phase 1
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Breast CancerPancreatic CancerOvarian Cancer+1 more
Qurgen Inc.150 enrolled5 locationsNCT05989724